Clinical Trial Update: Effectiveness of Synagis (Palivizumab) Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus (RSV) Infection

View source ↗

Summary

A completed trial evaluated the effectiveness of palivizumab immunoprophylaxis (Synagis) in high-risk preterm infants to prevent severe RSV infection; results w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Synagis (palivizumab)

Snippet

Sponsor: Abbott | Conditions: Respiratory Syncytial Virus Infection | Status: COMPLETED | Results posted: 2012-04-23